Literature DB >> 27870017

Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab.

Satheesh Chonat1, Shanmuganathan Chandrakasan1, Karen Ann Kalinyak1, David Ingala1, Ralph Gruppo1, Theodosia A Kalfa1.   

Abstract

Entities:  

Keywords:  atypical haemolytic uraemic syndrome; complement mutations; eculizumab; sickle cell disease; thrombotic microangiopathy

Mesh：

Substances：

Year:  2015        PMID： 27870017      PMCID： PMC5545798          DOI： 10.1111/bjh.13884

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  Alternative complement pathway assessment in patients with atypical HUS.

Authors:  Lubka T Roumenina; Chantal Loirat; Marie-Agnes Dragon-Durey; Lise Halbwachs-Mecarelli; Catherine Sautes-Fridman; Veronique Fremeaux-Bacchi
Journal:  J Immunol Methods       Date:  2011-01-06       Impact factor: 2.303

2.  Thrombotic thrombocytopenic purpura in a patient with sickle cell crisis.

Authors:  J Bolaños-Meade; Y K Keung; C López-Arvizu; R Florendo; E Cobos
Journal:  Ann Hematol       Date:  1999-12       Impact factor: 3.673

3.  How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome.

Authors:  Spero R Cataland; Haifeng M Wu
Journal:  Blood       Date:  2014-03-05       Impact factor: 22.113

Review 4.  A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome.

Authors:  Han-Mou Tsai
Journal:  Transfus Med Rev       Date:  2014-09-03

5.  The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.

Authors:  Junmei Chen; William E Hobbs; Jennie Le; Peter J Lenting; Philip G de Groot; José A López
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

6.  Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome.

Authors:  Tara K Maga; Carla J Nishimura; Amy E Weaver; Kathy L Frees; Richard J H Smith
Journal:  Hum Mutat       Date:  2010-06       Impact factor: 4.878

7.  Thrombotic microangiopathy in sickle cell disease crisis.

Authors:  Durjoy K Shome; Prabha Ramadorai; Abdulla Al-Ajmi; Fakhriya Ali; Neelam Malik
Journal:  Ann Hematol       Date:  2012-12-07       Impact factor: 3.673

8.  Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients.

Authors:  R H Wang; G Phillips; M E Medof; C Mold
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

9.  Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease.

Authors:  H E Lee; V J Marder; L J Logan; S Friedman; B J Miller
Journal:  Ann Hematol       Date:  2003-08-16       Impact factor: 3.673

10.  Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.

Authors:  Marie Frimat; Fanny Tabarin; Jordan D Dimitrov; Caroline Poitou; Lise Halbwachs-Mecarelli; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Blood       Date:  2013-05-21       Impact factor: 22.113
  10 in total
  2 in total

1.  Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease.

Authors:  Satheesh Chonat; Maa-Ohui Quarmyne; Caroline M Bennett; Christina L Dean; Clinton H Joiner; Ross M Fasano; Sean R Stowell
Journal:  Haematologica       Date:  2018-05-24       Impact factor: 11.047

Review 2.  Complement in Sickle Cell Disease: Are We Ready for Prime Time?

Authors:  Eleni Gavriilaki; Efthymia Vlachaki; Christos Varelas; Athina Tampaki; Ioanna Sakellari; Αchilles Anagnostopoulos
Journal:  J Blood Med       Date:  2021-03-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.